X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ELDER PHARMA ALEMBIC PHARMA/
ELDER PHARMA
 
P/E (TTM) x 16.7 -0.2 - View Chart
P/BV x 3.6 0.1 3,602.0% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 ALEMBIC PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ELDER PHARMA
Jun-14
ALEMBIC PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs664380 174.7%   
Low Rs412188 219.4%   
Sales per share (Unadj.) Rs208.7491.2 42.5%  
Earnings per share (Unadj.) Rs31.0-3.2 -974.3%  
Cash flow per share (Unadj.) Rs37.114.4 257.6%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.2376.5 38.3%  
Shares outstanding (eoy) m188.5220.54 917.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.6 446.0%   
Avg P/E ratio x17.4-89.3 -19.5%  
P/CF ratio (eoy) x14.519.7 73.6%  
Price / Book Value ratio x3.70.8 494.7%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,4615,833 1,739.3%   
No. of employees `000NANA-   
Total wages/salary Rs m7,4672,179 342.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m39,34710,089 390.0%  
Other income Rs m94257 36.6%   
Total revenues Rs m39,44110,346 381.2%   
Gross profit Rs m8,736-792 -1,103.1%  
Depreciation Rs m1,152361 318.9%   
Interest Rs m1842,756 6.7%   
Profit before tax Rs m7,493-3,653 -205.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m1,568125 1,252.5%   
Profit after tax Rs m5,844-65 -8,942.2%  
Gross profit margin %22.2-7.8 -282.9%  
Effective tax rate %20.9-3.4 -610.6%   
Net profit margin %14.9-0.6 -2,292.9%  
BALANCE SHEET DATA
Current assets Rs m19,5779,240 211.9%   
Current liabilities Rs m14,8969,998 149.0%   
Net working cap to sales %11.9-7.5 -158.4%  
Current ratio x1.30.9 142.2%  
Inventory Days Days9046 193.8%  
Debtors Days Days4560 75.7%  
Net fixed assets Rs m27,09710,124 267.7%   
Share capital Rs m377206 183.3%   
"Free" reserves Rs m26,8115,582 480.3%   
Net worth Rs m27,1887,734 351.6%   
Long term debt Rs m4,9934,889 102.1%   
Total assets Rs m47,77822,882 208.8%  
Interest coverage x41.7-0.3 -12,819.8%   
Debt to equity ratio x0.20.6 29.0%  
Sales to assets ratio x0.80.4 186.8%   
Return on assets %12.611.8 107.3%  
Return on equity %21.5-0.8 -2,543.5%  
Return on capital %23.622.3 105.8%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m19,453307 6,344.7%   
Fx outflow Rs m6,065125 4,840.2%   
Net fx Rs m13,388181 7,384.4%   
CASH FLOW
From Operations Rs m8,12011,754 69.1%  
From Investments Rs m-7,556-561 1,348.1%  
From Financial Activity Rs m590-6,762 -8.7%  
Net Cashflow Rs m1,1534,432 26.0%  

Share Holding

Indian Promoters % 74.1 39.6 187.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 16.8 54.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.1 38.5%  
Shareholders   49,328 16,479 299.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   AJANTA PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 318 Points Lower; Auto and Metal Stocks Witness Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 18, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS